首页> 外文期刊>NPJ systems biology and applications. >Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology
【24h】

Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology

机译:使用系统毒理学阐明与激酶抑制剂相关的不良反应的潜在分子机制

获取原文
           

摘要

Background/Objectives: Targeted kinase inhibitors are an important class of agents in anticancer therapeutics, but their limited tolerability hampers their clinical performance. Identification of the molecular mechanisms underlying the development of adverse reactions will be helpful in establishing a rational method for the management of clinically adverse reactions. Here, we selected sunitinib as a model and demonstrated that the molecular mechanisms underlying the adverse reactions associated with kinase inhibitors can efficiently be identified using a systems toxicological approach. Methods: First, toxicological target candidates were short-listed by comparing the human kinase occupancy profiles of sunitinib and sorafenib, and the molecular mechanisms underlying adverse reactions were predicted by sequential simulations using publicly available mathematical models. Next, to evaluate the probability of these predictions, a clinical observation study was conducted in six patients treated with sunitinib. Finally, mouse experiments were performed for detailed confirmation of the hypothesized molecular mechanisms and to evaluate the efficacy of a proposed countermeasure against adverse reactions to sunitinib. Results: In silico simulations indicated the possibility that sunitinib-mediated off-target inhibition of phosphorylase kinase leads to the generation of oxidative stress in various tissues. Clinical observations of patients and mouse experiments confirmed the validity of this prediction. The simulation further suggested that concomitant use of an antioxidant may prevent sunitinib-mediated adverse reactions, which was confirmed in mouse experiments. Conclusions: A systems toxicological approach successfully predicted the molecular mechanisms underlying clinically adverse reactions associated with sunitinib and was used to plan a rational method for the management of these adverse reactions.
机译:背景/目的:靶向激酶抑制剂是抗癌治疗剂中的重要一类药物,但其有限的耐受性妨碍了其临床表现。识别不良反应发生的分子机制将有助于建立临床不良反应管理的合理方法。在这里,我们选择舒尼替尼作为模型,并证明了使用系统毒理学方法可以有效地识别与激酶抑制剂相关的不良反应的分子机制。方法:首先,通过比较舒尼替尼和索拉非尼的人激酶占有率概况,筛选出候选毒理学候选物,并使用公开可用的数学模型通过顺序模拟预测不良反应的分子机制。接下来,为评估这些预测的可能性,对六名接受舒尼替尼治疗的患者进行了临床观察研究。最后,进行了小鼠实验,详细证实了所假设的分子机制,并评估了拟议对付舒尼替尼不良反应的对策的功效。结果:计算机模拟表明,舒尼替尼介导的脱磷酸酶抑制作用可能导致各种组织产生氧化应激。患者和小鼠实验的临床观察证实了该预测的有效性。模拟进一步表明,同时使用抗氧化剂可以预防舒尼替尼介导的不良反应,这在小鼠实验中得到了证实。结论:系统毒理学方法成功地预测了与舒尼替尼相关的临床不良反应的分子机制,并被用于规划合理的方法来管理这些不良反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号